Imperial Chemical Industries PLC saidit is forming a new U.S. pharmaceuticals unit called ICIPharma.    Combined sales of Imperial's existing StuartPharmaceuticals unit and the new ICI Pharma are projected to be1.1 billion dlrs in 1990, the company said.  Stuart had 1986sales of 582 mln dlrs.    Imperial said it plans to introduce several new drugs,including diprivan, an anaesthetic, and zestril, a heart drug,over the next three years. ICI Pharma and Stuart will operateas separate units of ICI Pharmaceuticals Group, it said.    Stuart Pharmaceuticals and ICI Pharma will have 1987 salesof approximately 700 mln dlrs, about 450 mln dlrs from the newICI Pharma and 250 mln dlrs from Stuart, officials said.    The combined sales force of about 900 sales people, splitabout equally between the two units, will be slightly largerthan the existing sales force at Stuart.    Regulatory approval for the annesthetic diprivan isexpected in late 1987, while zestril, a hypertension and heartdrug, should be approved in mid or late 1988, company officialssaid.    Approval for oth new drugs, including, statil, a treatmentfor diabetic complications, is not expected until 1989 and1990, the officials said. Reuter&#3;